PeptideStack
5.2kquestions
20kanswers
220users

How comparable are dulaglutide and semaglutide on the evidence available?

Asked 15 Aug 2024Modified 23 months agoViewed 29k times
38

Details up front: dulaglutide · semaglutide.

I suspect the honest answer is that it depends, in which case I would like to know on what.

Assume I can obtain either option without difficulty, so availability is not the deciding factor.

Under what conditions does the answer flip?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questionssemaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questionstirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questionsdulaglutide
dulaglutide

A once-weekly GLP-1 receptor agonist built on an Fc fusion rather than fatty-acid acylation. Use this tag for questions about the fusion-protein…

200 questions
shareeditfollowflag
BU
askedbufferline4230k13815 Aug 2024
6Worth saying whether you want relative or absolute risk. They read very differently. – fiadh_cronin 6 days ago
5Same question, and the two papers I found disagree, which is why I am watching. – Dr_Colm_Fitzhenry 8 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 29k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.